Overview

• The global CENTERSTONE Phase III trial, led by University of Michigan researchers, studied 1,457 flu patients and 2,681 household contacts.
• Findings show that a single dose of baloxavir marboxil reduces household transmission of influenza by approximately 30%.
• The drug significantly slows viral shedding, a key factor in flu transmission to close contacts.
• Unlike multi-day flu antivirals, baloxavir requires just one dose, potentially increasing patient adherence and treatment uptake.
• Laboratory studies suggest baloxavir may also inhibit avian influenza replication, indicating promise for pandemic preparedness.